Rio de Janeiro, Brazil XXI IFSO World Congress 2016
The 21st Wolrd Congress of IFSO, will be held in Rio de Janeiro, Brzail, September 27 - 1 October 2016. 2016-09-27 - 2016-10-01 |
MGBCON 2016
MGBCON 2016 19-20th August MGB/OAGB Consensus Conference London Annual conference of International MGB/OAGB Surgeons Club Dear Colleagues , On behalf of the International MGB/OAGB Club , it is our pleasure and honor to invite you to the MGBCON 2016, International MGB/OAGB…
MINI-GASTRIC BYPASS/ONE-ANASTOMOSIS GASTRIC BYPASS ANNUAL CONFERENCE
2016-08-19 - 2016-08-20 | Horley, Crawley, West Sussex , United Kingdom MINI-GASTRIC BYPASS/ONE-ANASTOMOSIS GASTRIC BYPASS ANNUAL CONFERENCE This will be an endeavour to quench the thirst of getting knowledge about the MGB/OAGB .All the MGB experts will be coming under…
BASE Study to examine bariatric patient experience
BASE Study In 2014, there were 889 bariatric surgeries performed in New Zealand A New Zealand study is assessing the bariatric surgery the surgical experience from the patient’s point of view, and examine how it has affected their life, the…
Ten year outcomes shows durability of RYGB
Long-term RYGB outcomes Study shows long-term reduction in comorbidities Roux-en-y gastric bypass is a durable operation for long-term weight loss and treatment of obesity-related comorbid disease, according to researchers from the University of Virginia, Charlottesville, VA. The study, which included…
Brains of overweight people ten years older vs lean people
Brain size and obesity Comparison of grey matter (brown) and white matter (yellow) in sex-matched subjects A (56 years, BMI 19.5) and B (50 years,) Researchers only observed these differences from middle-age onwards, suggesting that our brains may be particularly…
Insurance companies may now consider bariatric surgery
Insurance coverage New guidelines say surgery should also be considered for some mildly obese people with diabetes and a BMI between 30 and 40. Recent guidelines recommending bariatric surgery for obese people with Type 2 diabetes could convince more insurance…
Zafgen initiates multiple dose cohorts for ZGN-1061 Trial
Zafgen study The Phase 1 clinical trial is evaluating safety, tolerability, and weight loss efficacy over four weeks of treatment The company continues to expect top-line data from the clinical trial by the end of the first quarter of 2017…
FTO gene FTO gene does not affect weight loss
Carrying the risk version of the FTO gene had no effect on weight loss Carriers of the FTO gene are known to be on average 3kgs (6.6lbs) heavier and 70% more likely to be obese. However, researchers at Newcastle University,…
Stretta Therapy – a first line option for GERD
Stretta Therapy Gastroesophageal Reflux Disease (GERD) is estimated to affect 20% of the population in the USA1, this equates to approximately 65 million people from a population of 320 million people. Most patients manage reflux disease through medications (eg proton…